FDA scientists resisted White House plan to ease rules on peptide drugs

A White House-backed plan to relax FDA oversight on certain peptide drugs was opposed by most FDA scientific staff, who had little input in drafting the policy, according to Fast Company. The proposal, driven by Health Secretary Robert F. Kennedy Jr., would allow specialty pharmacies to sell some injectable peptides without the usual FDA review. The policy recently underwent regulatory review at the White House, which is typically the last step before publication.

This internal resistance signals regulatory uncertainty for pharma and healthcare leaders, as FDA staff warned the move could undermine the agency’s mission to keep unproven drugs off the market. Senior executives should monitor how these divisions affect enforcement and compliance expectations.